September 23rd 2024
The option gives Glaukos exclusive global license agreements on pre-agreed terms, including upfront and milestone payments plus royalties.
Trinity geneticists develop novel gene therapy for glaucoma
April 21st 2023Researchers at the Smurfit Institute of Genetics, in collaboration with the biotechnology company Exhaura Ltd., have shown that a gene therapy-based approach can decrease intraocular pressure in pre-clinical models of glaucoma.
Read More
Glaucoma 360: Drug targets and reduces episcleral venous pressure in glaucoma
February 3rd 2023Thurein Htoo, MS, MBA, CEO and co-founder of Qlaris Bio, took the podium at the New Horizons Forum at the Glaucoma 360 conference in San Francisco to discuss the performance of the company’s episcleral venous pressure eyedrop, QLS-111.
Read More
Nicox outlines future development, partnership plans for NX 470 in glaucoma
November 7th 2022The company said it plans to generate clinical data aiming to demonstrate the potential retinal benefits of NCX 470 in order to add significant therapeutic value to the product profile in glaucoma.
Read More
NIH backing first-in-class engineered mechanosensitive channel based gene therapy for glaucoma
October 9th 2022Nanoscope Technologies LLC announced this week it has received Direct Phase II SBIR grant from National Institutes of Health for developing an innovative approach to autonomously regulate pressure for treatment of Glaucoma in a gene-agnostic manner.
Read More
The need for precision management in glaucoma moves field forward
September 28th 2022Genotyping and artificial intelligence are together starting to predict the progression of glaucoma in individual patients, sparing them from suboptimal treatments and adverse effects. Recent research efforts are exploring modifiable risk factors such as caffeine consumption.
Read More
A research team led by the Department of Ophthalmology, School of Clinical Medicine, LKS Faculty of Medicine of The University of Hong Kong, with collaborators from the Faculty of Medicine of The Chinese University of Hong Kong and local and international partners, have developed a new technology ROTA to unveil the optical texture and trajectories of the axonal fiber bundles on the retina.
Read More
Nicox’s NCX 470 Dolomites Phase 2 results published in Journal of Glaucoma
April 11th 2022NCX 470 is currently enrolling patients in two multi-regional Phase 3 glaucoma clinical trials, Mont Blanc and Denali. The objective of these two trials is to demonstrate statistically superior IOP lowering of once daily dosed NCX 470
Read More
Micro-bypass stent implant during cataract surgery: lower IOP, fewer medications
July 25th 2021Mark Gallardo, MD, reports 12-month outcomes of iStent inject® combined with cataract surgery in a predominantly Hispanic patient population with mild to moderate open-angle glaucoma (OAG) and comorbid cataract.
Read More